Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis

NCT00728507 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT00728507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00728507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis
Lead sponsor
Johns Hopkins University
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2009
Completion date
April 30, 2013
Enrollment
121 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis